The cholesterol drug obicetrapib may lower the risk of Alzheimer’s in APOE4/4 carriers.
This is exciting news because people with APOE4/4 are typically told there is no treatment that can lower their high risk.
This class of cholesterol drugs, CETP inhibitors, has not worked well against CVD so far. But the results with Alzheimer’s look very promising.
Quoted:
If you are APOE4/4 and you've been told genetics is destiny for 20 years — read this.
Pre-specified BROADWAY substudy. 1,535 patients. APOE4/4 homozygotes had the LARGEST benefit of any subgroup. All five biomarkers moved correctly — p-tau217, Abeta42/40, p-tau217/Abeta ratio, GFAP, NfL. Placebo-adjusted benefits 13.67 to 22.65 percent. GFAP alone: -6.39% on obicetrapib vs +8.85% on placebo. Davidson and colleagues wrote: "first demonstration of an oral intervention capable of reducing both beta-amyloid and tau pathology biomarkers in ApoE4 carriers." This is education, not medical advice. Caveats: biomarker not cognitive outcome, subgroup is 1,535-total slice, needs replication. I got emotional reading this paper.
Full breakdown at the link in bio.
#obicetrapibHD #cetpinhibitorHD #apoe4HD #alzheimersHD #ptau217HD #amyloidHD #dementiaHD


